IL311670A - Resmetirom for reducing liver volume - Google Patents
Resmetirom for reducing liver volumeInfo
- Publication number
- IL311670A IL311670A IL311670A IL31167024A IL311670A IL 311670 A IL311670 A IL 311670A IL 311670 A IL311670 A IL 311670A IL 31167024 A IL31167024 A IL 31167024A IL 311670 A IL311670 A IL 311670A
- Authority
- IL
- Israel
- Prior art keywords
- resmetirom
- liver
- volume
- reducing
- Prior art date
Links
- 210000004185 liver Anatomy 0.000 title 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 title 1
- 229940121486 resmetirom Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248634P | 2021-09-27 | 2021-09-27 | |
| PCT/US2022/044826 WO2023049491A1 (en) | 2021-09-27 | 2022-09-27 | Resmetirom for reducing liver volume |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311670A true IL311670A (en) | 2024-05-01 |
Family
ID=83900064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311670A IL311670A (en) | 2021-09-27 | 2022-09-27 | Resmetirom for reducing liver volume |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240408102A1 (enExample) |
| EP (2) | EP4578499A3 (enExample) |
| JP (1) | JP2024536126A (enExample) |
| KR (1) | KR20240073926A (enExample) |
| CN (1) | CN118251221A (enExample) |
| AR (1) | AR127165A1 (enExample) |
| AU (1) | AU2022348966A1 (enExample) |
| CA (1) | CA3233319A1 (enExample) |
| CL (1) | CL2024000886A1 (enExample) |
| IL (1) | IL311670A (enExample) |
| MX (1) | MX2024003967A (enExample) |
| TW (1) | TW202337470A (enExample) |
| WO (1) | WO2023049491A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024251233A1 (zh) * | 2023-06-08 | 2024-12-12 | 成都微芯药业有限公司 | PPAR全激动剂联合THR-β激动剂在抗代谢相关疾病中的用途 |
| JP2026521649A (ja) * | 2023-06-22 | 2026-06-30 | マドリガル ファーマシューティカルズ インコーポレイテッド | ＴＨＲ－βアゴニストを用いて肝障害を治療するためのバイオマーカーおよび関連する使用 |
| KR20260000642A (ko) * | 2024-06-25 | 2026-01-05 | 연세대학교 산학협력단 | Usp10 억제제를 유효성분으로 포함하는, 간섬유증 또는 간섬유증 관련 질환의 예방 또는 치료용 조성물 |
| WO2026107045A1 (en) * | 2024-11-12 | 2026-05-21 | Madrigal Pharmaceuticals, Inc. | Resmetirom for use in treating cardiomyopathy and/or related heart failure and portal hypertension |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE480524T1 (de) | 2005-07-21 | 2010-09-15 | Hoffmann La Roche | Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| ES2795450T3 (es) | 2012-09-17 | 2020-11-23 | Madrigal Pharmaceuticals Inc | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| MX394463B (es) | 2016-10-18 | 2025-03-19 | Madrigal Pharmaceuticals Inc | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. |
| TW202615431A (zh) | 2018-07-02 | 2026-04-16 | 美商瑪德瑞高製藥公司 | ２－（３，５－二氯－４－（（５－異丙基－６－側氧基－１，６－二氫噠嗪－３－基）氧）苯基）－３，５－二側氧基－２，３，４，５－四氫－１，２，４－三嗪－６－腈之固體型式 |
| CA3111025C (en) * | 2018-09-06 | 2023-10-31 | Galmed Research And Development Ltd | Combination therapy for the treatment of liver disease |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| CA3195960A1 (en) | 2020-10-23 | 2022-04-28 | Madrigal Pharmaceuticals, Inc. | Process for the preparation of 6-(4-nitro-phenoxy)-2h-pyridazin-3-one and 6-(4-amino-phenoxy)-2h-pyridazin-3-one derivatives as intermediates of thyroid hormone analogues |
-
2022
- 2022-09-27 TW TW111136510A patent/TW202337470A/zh unknown
- 2022-09-27 IL IL311670A patent/IL311670A/en unknown
- 2022-09-27 EP EP24212126.7A patent/EP4578499A3/en active Pending
- 2022-09-27 MX MX2024003967A patent/MX2024003967A/es unknown
- 2022-09-27 US US18/695,572 patent/US20240408102A1/en active Pending
- 2022-09-27 CN CN202280075697.1A patent/CN118251221A/zh active Pending
- 2022-09-27 EP EP22793025.2A patent/EP4408428A1/en not_active Withdrawn
- 2022-09-27 JP JP2024519112A patent/JP2024536126A/ja active Pending
- 2022-09-27 CA CA3233319A patent/CA3233319A1/en active Pending
- 2022-09-27 AR ARP220102600A patent/AR127165A1/es unknown
- 2022-09-27 KR KR1020247013928A patent/KR20240073926A/ko active Pending
- 2022-09-27 WO PCT/US2022/044826 patent/WO2023049491A1/en not_active Ceased
- 2022-09-27 AU AU2022348966A patent/AU2022348966A1/en active Pending
-
2024
- 2024-03-26 CL CL2024000886A patent/CL2024000886A1/es unknown
-
2025
- 2025-11-12 US US19/386,839 patent/US12661361B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20260069598A1 (en) | 2026-03-12 |
| JP2024536126A (ja) | 2024-10-04 |
| MX2024003967A (es) | 2024-06-03 |
| US12661361B2 (en) | 2026-06-23 |
| AU2022348966A1 (en) | 2024-04-11 |
| US20240408102A1 (en) | 2024-12-12 |
| CN118251221A (zh) | 2024-06-25 |
| EP4408428A1 (en) | 2024-08-07 |
| CL2024000886A1 (es) | 2024-08-30 |
| KR20240073926A (ko) | 2024-05-27 |
| WO2023049491A1 (en) | 2023-03-30 |
| AR127165A1 (es) | 2023-12-27 |
| CA3233319A1 (en) | 2023-03-30 |
| EP4578499A2 (en) | 2025-07-02 |
| TW202337470A (zh) | 2023-10-01 |
| EP4578499A3 (en) | 2025-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292753A (en) | Compounds | |
| DK4165024T3 (da) | Cyclobutyldihydroquinolinsulfonamid-forbindelser | |
| EP4129997A4 (en) | Octahydropyrazinodiazanaphthyridine dione compounds | |
| DK4083038T3 (da) | Pyridazinylthiazolcarboxamidforbindelse | |
| IL310528A (en) | Pyrazolopyridinone compounds | |
| DK4055021T3 (da) | Heterocykliske rip1-inhiberende forbindelser | |
| EP4293025C0 (en) | COMPOSED WITH 4-AMINOQUINAZOLINE | |
| DK4051688T3 (da) | Cd73-hæmmere | |
| EP3483158A4 (en) | HETEROCYCLIC COMPOUND SERVING AS FGFR4 INHIBITOR | |
| EP4149556C0 (en) | PEG LIPIDOIDS COMPOUNDS | |
| DK4320112T3 (da) | Pyridinylsubstituerede oxoisoindolinforbindelser | |
| IL289111A (en) | Uridine phosphorylase (upase) inhibitors for treatment of liver conditions | |
| DK4090815T3 (da) | Flange | |
| EP4003986A4 (en) | Inhibitor compounds | |
| IL285546A (en) | Compounds and methods for reducing kcnt1 expression | |
| EP4457967A4 (en) | MULTI-MICROCHIP CLOCK DELAY COMPENSATION | |
| EP4143199C0 (en) | NUCLEOTIDE PROMEDICINAL COMPOUNDS | |
| EP3861763A4 (en) | Highlighting audio spatialization | |
| EP4401766A4 (en) | Neo-antigenic anti-Kras therapies | |
| EP3738603A4 (en) | NTCP INHIBITOR | |
| IL291221B2 (en) | Methods for the synthesis of wolbenzen | |
| PT4038149T (pt) | Compostos anti-incrustação | |
| EP4006037A4 (en) | HETEROCYCLIC COMPOUND | |
| IL313590A (en) | Compounds | |
| IL290031A (en) | Aminothiolester compounds and uses thereof |